The European Community's Committee for ProprietaryMedicinal Products (CPMP) has recommended approval ofSchering-Plough Corp.'s Intron A alpha interferon for treatingchronic active hepatitis C.
In EC countries, about 240,000 people annually become acutelyinfected with hepatitis C (non-A, non-B hepatitis). Of these,about 50 percent develop a chronic form. Three EC countries --Greece, Italy and Portugal -- have already approved Intron Afor hepatitis C.
Intron A received U.S. marketing approval for hepatitis C inFebruary. Intron A also has U.S. marketing approval fortreatment of hairy cell leukemia, venereal warts and Kaposi'ssarcoma.
In December, the CPMP recommended approval of Intron A forchronic hepatitis B, and it has been approved for this indicationin nine EC countries.
Schering (NYSE:SGP) of Madison, N.J., licensed Intron A fromBiogen Inc. of Cambridge, Mass., in the late 1970s. Schering hasmore than 50 percent of the $500 million worldwide marketfor alpha interferon, said James Vincent, chairman and chiefexecutive of Biogen. Biogen (NASDAQ:BGEN) receives royaltiesof between 10 percent and 20 percent on Schering's Intron Asales.
-- Karen Bernstein BioWorld Staff
(c) 1997 American Health Consultants. All rights reserved.